Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets

P Vihinen, VM Kähäri - International journal of cancer, 2002 - Wiley Online Library
… as prognostic indicators in cancer is studied. In addition, therapeutic intervention of tumour
… of MMPs as prognostic markers and as targets for therapeutic intervention in cancer. © 2002 …

Y-box binding protein 1–a prognostic marker and target in tumour therapy

C Kosnopfel, T Sinnberg, B Schittek - European journal of cell biology, 2014 - Elsevier
… be an attractive target for tumour therapy, due to its versatility, there is still much need for
development and thorough pre-clinical evaluation of a suitable therapeutic strategy in order to …

Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis

AM Jubb, FM Buffa, AL Harris - Journal of cellular and …, 2010 - Wiley Online Library
prognostic markersprognostic marker in several publicly available breast cancer datasets,
high expression of the lactic acidosis response signature was associated with good prognosis

Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets

E Hadler-Olsen, JO Winberg, L Uhlin-Hansen - Tumor Biology, 2013 - Springer
… are not commonly used as prognostic markers or in treatment stratification in … prognostic
markers. The combination of several MMPs or MMPs together with other prognostic markers

Evidence for the clinical use of tumour markers

MJ Duffy - Annals of clinical biochemistry, 2004 - journals.sagepub.com
prognosis in patients non-seminomatous germ cell tumours, CA 125 for monitoring therapy
in … PAI-1 are potent and independent prognostic markers in breast cancer. Although not yet in …

[HTML][HTML] Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances

G Lech, R Słotwiński, M Słodkowski… - World journal of …, 2016 - ncbi.nlm.nih.gov
… Other studies have demonstrated that plasma VEGF-A may serve as a prognostic marker,
but is unable to predict response to VEGF-targeted therapy in advanced CRC[94,95]. At the …

[HTML][HTML] BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

SJ Dawson, N Makretsov, FM Blows, KE Driver… - British journal of …, 2010 - nature.com
… The aim of the current study was to prospectively test the clinical validity of BCL2 as a
prognostic marker independent of ER, HER2 and adjuvant therapy received, in addition to tumour

Molecular prognostic markers in pancreatic cancer: a systematic review

G Garcea, CP Neal, CJ Pattenden, WP Steward… - European journal of …, 2005 - Elsevier
… Molecular markers could also be measured in surrogate tissue such as sera, allowing …
following tumour resection or their response to medical therapy. Finally, these molecular markers

Prognostic versus predictive value of biomarkers in oncology

C Oldenhuis, SF Oosting, JA Gietema… - European journal of …, 2008 - Elsevier
prognostic marker must be a proven independent, significant factor, that is easy to
determine and interpret and has therapeutic … reporting tumour marker prognostic studies (REMARK). …

Molecular predictive and prognostic markers in non-small-cell lung cancer

LE Coate, T John, MS Tsao, FA Shepherd - The lancet oncology, 2009 - thelancet.com
… Platinum-based chemotherapy is the therapeutic foundation of treatment both in the …
Defining predictive and prognostic markers A prognostic factor is a patient or tumour characteristic …